I don't know @stoneral33 from next guy on the street, but if you read his posts he has lost a bit of $$ on this stock, but got our before current misery.
And once again AGH full suite of licences does nothing for it, especially the bottom line without a growing/manufacturing facility, which is at least 12 months away, then to produce a product, even longer, ah!
Patient numbers will grow as they have been until other players in the local market start producing their own product & their margin will be healthy than on imported products. Minimal competition atm, won't be so for too much longer.
Even with 1000 patients, how much revenue (cut from Alphria) does that bring anyway?
Importing products just ticking a box so ODC will allow you to export home grown products globally, that's where real $$ can be made.
That 39M will go & more on facility etc don't worry about that.
.
AGH Price at posting:
19.5¢ Sentiment: Hold Disclosure: Not Held
